Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin.

Francesco D'Alo', Stefan Hohaus, Maria Chiara Tisi, Valentina Bozzoli, Manuela Giachelia, Giuseppina Massini, Bianca Maria Ricerca Storti, Elena Maiolo, Luigi Maria Larocca, Alfonso Piciocchi, Maria Teresa Voso, Giuseppe Leone, Harold Tjalsma, Dorine W. Swinkels

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

34 Citazioni (Scopus)


Anemia is a frequent sign in patients with diffuse large B-cell lymphoma (DLBCL) at diagnosis. We determined erythropoietin, hepcidin and interleukin-6 (IL-6) in plasma samples of 53 patients with DLBCL. The majority of patients (40/53, 75%) showed defective endogenous erythropoietin production, in particular when anemia was present (p = 0.01). Hepcidin plasma levels were significantly higher in patients compared to controls (p = 0.006), particularly in those with characteristics associated with a more active disease, including elevated lactate dehydrogenase (LDH) (p = 0.0004), B-symptoms (p = 0.07) and an age-adjusted international prognostic index (IPI) score > 1 (p = 0.01). Hepcidin levels correlated strongly to ferritin (r = 0.77, p < 0.0001) and weakly to IL-6 concentrations (r = 0.30, p = 0.03), but not to hemoglobin values. IL-6 inversely correlated to hemoglobin values in both univariate and multivariate analysis (p = 0.04), including hepcidin and erythropoietin as variables. Our findings suggest that elevated hepcidin levels and inadequate erythropoietin response are frequent in DLBCL, but elevated IL-6 plays the major role for the development of anemia.
Lingua originaleEnglish
pagine (da-a)270-275
Numero di pagine6
Stato di pubblicazionePubblicato - 2014


  • Lymphoma
  • anemia


Entra nei temi di ricerca di 'Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin.'. Insieme formano una fingerprint unica.

Cita questo